Quanterix (QTRX) Stock
Small diagnostics maker with sensitive instruments for research. Here's the price, business snapshot, and what's worth knowing about Quanterix in August 2026.
Quanterix Corporation (QTRX) is a small-cap diagnostics company that makes ultra-sensitive immunoassay instruments and assays under its Simoa (single molecule array) platform. Investors should know Quanterix sells analytical instruments and consumable assays used by research labs and clinical partners to detect low-abundance biomarkers across neurology, oncology and other fields. The business model mixes instrument sales with recurring reagent and service revenues, but growth depends on broader clinical adoption of its assays, partnership deals, and continued product development. With a market cap near $281.6m, the company faces typical biotech and device risks — regulatory hurdles, competition from incumbent laboratory platforms, and periodic capital needs. Potential upside comes from expanded clinical use, higher reagent attach rates and new assays, while performance can be volatile and past performance is not a guide to future returns. This is general educational information, not personalised investment advice.
About This Stock
QUANTERIX CORPORATION
QTRX
Current Price
$2.88
Potential 12 Month Profit
288.46%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Ticker
QTRX
Market Cap
$139.99M
Potential 12 Month Profit
288.46%
Sector
Healthcare
Industry
Healthcare Equipment & Supplies
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Quanterix Corporation's stock as its value might not increase significantly soon.
Financial Health
Quanterix Corporation is generating strong revenue and cash flow, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue potential
Instrument sales can lead to steady consumable and reagent revenue, which may support long-term growth — though recurring sales can vary with adoption rates.
Clinical adoption focus
Wider use of Simoa assays in neurology and oncology could expand addressable markets, but adoption depends on regulatory approval and clinician uptake.
Technology edge
Ultra‑sensitive single-molecule detection differentiates the platform; however, competition and execution risks mean outcomes can be uncertain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.